Evelo Biosciences, Inc. (NASDAQ:EVLO) Q2 2020 Earnings Conference Call - Final Transcript
Jul 30, 2020 • 08:30 am ET
Good morning, and welcome to the Evelo Biosciences Second Quarter 2020 Financial and Operating Results Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the Company's request.
At this time, I'd like to turn it over to Jessica Cotrone of Evelo. Please proceed.
Thank you, operator. Good morning, everyone. This morning, we issued a press release that outlines the topics we plan to discuss today. This release is available at www.evelobio.com under the Investors tab.
Today on our call, Simba Gill, Chief Executive Officer; Mark Bodmer, President of R&D and Chief Scientific Officer; and Duncan McHale, Chief Medical Officer, will review our second quarter 2020 financial results and recent business highlights.
Before we begin, I'd like to remind everyone that statements made during this conference call that do not relate to matters of historical facts, including statements about our objectives and anticipated clinical milestones for 2020, the impact of any of our monoclonal microbials and the timing and results of any clinical studies, and the sufficiency of cash to fund operations, should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual results could differ materially from those indicated by the forward-looking statements due to the impact of many factors. Participants are directed to the risk factors set forth in Evelo's quarterly report on Form 10-Q for the quarter ended June 30, 2020, and the Company's other filings with the Securities and Exchange Commission. Any forward-looking statements made today speak only to Evelo's operations as of today. Evelo disclaims any duty to provide updates to its forward-looking statements even if subsequent events cause the Company's views to change.
It is now my pleasure to pass the call over to Simba.
Thank you, Jessica. Good morning, everyone, and thanks for joining us to review our progress during the second quarter. This is an exciting and important time for us. We've recently completed our follow-on offering, which provides the capital to advance our programs in inflammation and oncology through the next phases of clinical development, while continuing to invest in our platform and our pipeline.
We expect to generate six clinical readouts within the next six to 12 months, including data from our Phase 2 dose ranging study with EDP1815 in psoriasis, data from the Phase 2 and Phase 2/3 trials of EDP1815 in COVID-19, additional data from the Phase 1/2 trial of EDP1503 in triple-negative breast cancer, and data from two Phase 1 trials in atopic dermatitis, with each of EDP1815 and EDP1867.
Our vision is to harness the small intestinal axis, or SINTAX, to develop a new class of medicines that are effective, safe, convenient and affordable. In both our inflammatory and oncology programs, we have demonstrated that the effects observed in preclinical models translate to humans, showing that we can harness SINTAX to modulate clinically relevant pathways.
As you know,